本期HMS-CSSA创业沙龙请到了启明创投（Qiming Venture Partners）的管理合伙人

梁颖宇（Nisa Leung）来为大家分享生物科技投资的经验和故事

Nisa Leung (梁颖宇) is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages over USD 3 billion in assets and investment in over 240 companies.

Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017 and Top 3 Best Female Venture Capitalist by Forbes in 2018. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology and Berry Genomics (SZSE:000710). Her other investments include Acea Biosciences, Aeonmed Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, New Horizon Bio and Jacobio.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, a founding member and Vice Chair of PhIRDA Investment Committee, member of Committee on Hong Kong Innovation and Technology (I&T) Development and Re-Industrialization, advisor of Our Hong Kong Foundation, founder of Venture Investors Alliance of Hong Kong, council member of HKUST Business School and serves on the Board of Governors of the Hotchkiss School.